Bloomberg reports that the world’s largest healthcare company Johnson & Johnson is in talks with Cardinal Health Inc. to sell its Cordis unit. The unit may fetch as much as $2 billion in a sale, according to the story.
The company’s heart devices such as implantable defibrillators, artificial valves and devices to treat atrial fibrillation, contributed to a 5 percent increase in sales in the cardiac and vascular business, its largest unit.
According to recent analysis by PwC, deal volume declined from 13 deals in the third quarter of 2014 to 9 deals in the fourth quarter. However, deal value increased from $3.7 billion to $4.9 billion over the same period.
The new PMD Act was based on previous ordinances implemented in the summer of 2014. Two of the main points of this revision are to increase safety measures for medical devices and introduce new cellular and tissue therapeutic product regulations.
The medical device tax has a “profound negative effect” on the nation’s jobs and innovation, AdvaMed President and CEO Stephen Ubl and Medical Imaging & Technology Alliance Executive Director Gail Rodriguez explain in an editorial.
Many remote patient monitoring and management solutions today require patients to communicate results to their health care professionals in manual, time-consuming and non-digitized channels. Qualcomm Life and Roche hope to create an improved process for sharing health information between health care providers and their patients.
This Q&A session, with an active Regional Medical Director involved in traditional health plan policy and payment development, as well as emerging value-based models, reveals important information and attitudes toward coverage of new/existing technologies and standards of evidence.
New market research report also notes that growth has been restricted by a lack of standardization of policies related to the reuse of medical devices and the hesitancy of some organizations to purchase refurbished medical equipment.
Medtronic has completed the 50 billion acquisition of Covidien, in the largest medical device merger of all time.
The U.S. Medical Device Excise Tax continues to draw scorn from industry advocates as a jobs killer. However, new data from a survey tells a different story about how executives are compensating for costs of the tax, and that story varies considerably by size of company.